The grant will be used to explore Cayman’s patented small molecule bone repair agent KMN-159 as the active pharmaceutical ingredient (API) in a drug-device combination to improve the mechanical anchorage of dental titanium implants into the jawbone.
Lead Product(s): KMN-159,Collagen
Therapeutic Area: Musculoskeletal Product Name: KMN-159
Highest Development Status: PreclinicalProduct Type: Small molecule
Deal Size: $1.7 million Upfront Cash: Undisclosed
Deal Type: Funding September 16, 2021
The funding will be used to develop an assay platform and novel antibodies to support the treatment, prevention, and early diagnosis of Alzheimer’s disease and other tauopathies.
Lead Product(s): Antibody
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding October 08, 2020